Physician profile
Ryan Kumar Singhi
NPI 1568882009
$9,268.11
in general payments reported to CMS, 2019-2025
49 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $2,888 · 2021: $1,637 · 2022: $1,421 · 2023: $1,824 · 2024: $532 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,425.39 | 2019-2020 | |
| Abbott Laboratories | $914.85 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $625.44 | 2019-2024 | Mounjaro, Humulin, Trulicity |
| Sanofi-Aventis U.S. LLC | $591.62 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $544.60 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.21 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $450.59 | 2019-2023 | Korlym |
| Mannkind Corporation | $427.97 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $390.65 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Dexcom, INC. | $348.01 | 2021-2024 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $327.73 | 2019-2023 | Unithroid |
| Amarin Pharma, INC. | $313.54 | 2019-2022 | |
| Amgen INC. | $243.01 | 2019-2025 | Tepezza, Repatha, Prolia |
| Horizon Therapeutics Plc | $215.69 | 2020-2022 | |
| Abbvie INC. | $176.88 | 2020-2024 | Synthroid |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Singhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.